Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for transfer factor as a treatment for multiple sclerosis, effective May 15, 2026. Here's what billing teams need to know before that date.
CMS transfer factor coverage policy has historically been one of the more straightforward non-coverage positions in the Medicare program. This modification signals a formal policy review cycle — and billing teams submitting claims for MS-related immunotherapy should understand what CMS's position means for reimbursement and claim denial risk. The policy does not list specific CPT or HCPCS codes in the source data, so the code discussion below reflects the clinical context of the therapy rather than a code-mapped list.
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Transfer Factor for Treatment of Multiple Sclerosis |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium — affects neurology and infusion billing teams submitting MS-related claims |
| Specialties Affected | Neurology, infusion therapy, immunology, primary care managing MS patients |
| Key Action | Audit any pending or recurring claims for transfer factor in MS patients before May 15, 2026 and confirm coverage status before submitting |
CMS Transfer Factor for Multiple Sclerosis Coverage Criteria and Medical Necessity Requirements 2026
The Centers for Medicare & Medicaid Services has maintained a long-standing position that transfer factor — a leukocyte-derived extract intended to modulate immune response — is not established as a safe and effective treatment for multiple sclerosis under Medicare billing guidelines. This policy modification, effective May 15, 2026, represents a formal update to that position. Whether CMS has shifted the criteria, clarified language, or reinforced the existing non-coverage stance, your billing team needs to treat this as an active policy review and not a background event.
Transfer factor billing under Medicare has always carried claim denial risk when submitted for MS indications. CMS's medical necessity standard requires that a service be reasonable and necessary for the diagnosis or treatment of illness or injury. Transfer factor has not met that bar under the Medicare evidence standard for MS — and this policy reflects that assessment in updated form.
The source data for this policy does not include the full revised text, so the specific criteria language CMS used in this modification is not available here. That matters for your team. If you're billing for any immunomodulatory infusion therapy in MS patients and there's any ambiguity about the product being administered, confirm the exact coverage policy language before the effective date of May 15, 2026.
Prior authorization won't resolve a non-covered service designation. If CMS classifies transfer factor for MS as non-covered, no prior auth path exists to override that under traditional Medicare. Medicare Advantage plans may handle this differently — but your MAC's local guidance governs fee-for-service claims.
CMS Transfer Factor for MS Exclusions and Non-Covered Indications
CMS's existing position on transfer factor for multiple sclerosis treatment falls under the broader framework of services that lack sufficient clinical evidence to meet the reasonable and necessary standard. This is the same framework CMS uses when classifying experimental or investigational treatments across other therapeutic areas.
Transfer factor is not the same as disease-modifying therapies with established Medicare coverage. It's a separate product category — typically derived from pooled human leukocytes — and the clinical evidence supporting its use in MS has not met the threshold CMS applies to covered neurological treatments. This is not a gray area under Medicare's standard.
The real issue for billing teams is that transfer factor sometimes gets submitted under broader immunotherapy or infusion codes without clear indication documentation. That's where exposure lives. If the diagnosis on the claim points to MS and the service involves transfer factor, CMS's coverage policy makes that a non-covered claim — regardless of how the code is structured.
Coverage Indications at a Glance
The source policy data does not include a detailed, indication-by-indication breakdown with mapped codes. The table below reflects the known CMS position based on the policy title and established Medicare coverage framework.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Transfer factor as treatment for multiple sclerosis | Not Covered | Not specified in policy data | CMS does not consider this service reasonable and necessary for MS under Medicare; claim denial is expected |
| Transfer factor for other indications (non-MS) | Varies by indication | Not specified in policy data | Coverage status depends on the specific diagnosis and any applicable local coverage determination from your MAC |
| MS treatment via established disease-modifying therapies | Covered when criteria met | Per applicable drug or infusion policy | Separate from this policy; standard MS billing guidelines apply |
CMS Transfer Factor for Multiple Sclerosis Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Audit your open and recurring claims now. Before May 15, 2026, pull any claims in your queue or recurring billing cycles that involve transfer factor with an MS diagnosis. This is especially relevant for infusion practices or neurology groups that bill a high volume of MS-related services. |
| 2 | Review your charge capture for infusion codes tied to MS patients. If your team bills infusion administration codes for MS patients receiving immunomodulatory products, confirm the exact product administered. Transfer factor is not interchangeable with approved disease-modifying therapies, and mixing them up in documentation creates both a claim denial problem and a compliance risk. |
| 3 | Check with your MAC for any local coverage determination (LCD) that applies. CMS sets the national coverage framework, but your Medicare Administrative Contractor may have issued an LCD that provides additional guidance or criteria for immunotherapy billing in neurological conditions. Check your MAC's website before May 15, 2026 — don't assume the national policy is the only document that applies. |
| 4 | Do not rely on prior authorization as a workaround. For services CMS designates as non-covered under a national policy, prior auth does not create a reimbursement path under traditional Medicare. If your team has been seeking prior auth for transfer factor in MS patients, stop. The coverage policy itself is the barrier, not the authorization process. |
| 5 | Update your payer contract and coverage reference materials. If your practice or revenue cycle team maintains an internal coverage reference guide, update the entry for CMS MS treatments to reflect this policy modification with an effective date of May 15, 2026. |
| 6 | Talk to your compliance officer if you have mixed Medicare Advantage and fee-for-service MS patients. Medicare Advantage plans sometimes diverge from national CMS coverage policy. If you serve MS patients across both plan types and have any transfer factor-related billing in your workflow, your compliance officer should review the plan-level contracts before the effective date. Don't let a Medicare Advantage prior auth approval lead you to assume fee-for-service coverage follows. |
| 7 | Document clearly when MS patients receive covered therapies. The risk of inadvertent claim denial goes up when documentation is loose. If a patient is receiving an approved MS therapy, the records should clearly name the product, the indication, and the medical necessity rationale. Don't leave room for a claim to be read as transfer factor billing. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Transfer Factor Under CMS MS Coverage Policy
The source policy data does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is a known limitation of the available policy data for this modification.
Do not infer or apply codes based on general knowledge of similar policies. Billing transfer factor under an incorrect code to work around a non-coverage position creates false claims exposure. The right path is to confirm the exact coding guidance with your MAC or your compliance officer.
What to Look For When Researching Codes
If your billing team needs to identify the correct codes for this policy, start with these steps:
- Search the CMS Coverage Database for any National Coverage Determination (NCD) tied to transfer factor or MS immunotherapy
- Check your MAC's LCD search tool using the diagnosis term "multiple sclerosis" and the therapy category "immunotherapy" or "biological agents"
- Review HCPCS Level II codes in the J-code range for biologic and immunotherapy products — your MAC's LCD may specify which codes apply under this policy
Key ICD-10-CM Codes Relevant to Multiple Sclerosis Billing
While the policy data does not specify ICD-10 codes, the following diagnosis codes are the standard codes your billing team will encounter when submitting MS-related claims. These are not policy-specified — confirm their applicability with your MAC.
| Code | Description |
|---|---|
| G35 | Multiple sclerosis |
| G36.0 | Neuromyelitis optica (Devic's disease) — sometimes coded alongside MS differentials |
| G37.9 | Demyelinating disease of central nervous system, unspecified |
Again — these are standard ICD-10 reference codes for context only. The policy source data does not include a mapped code list. If your MAC or a future update to this policy includes specific codes, those supersede this reference.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.